Invesco Nasdaq Biotechnology ETF

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

Insmed's New Drug BRINSUPRI Sales Surge 44%, CEO Lewis Reaffirms Growth Confidence

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Biogen announces Alzheimer's drug fails to meet primary endpoint in mid-stage trial

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)

ATYR

SBIO

IBBQ

LABU

RBC Capital has maintained a Hold rating on aTyr Pharma (ATYR) with a price target of $1.00, while the shares closed at $0.50. Analyst Brian Abrahams has an average return of 10.7% and a 52.10% success rate. Wells Fargo also issued a Hold rating, while Piper Sandler maintained a Buy rating on May 12.

Tip Ranks

ATYR Pharma

ALPS Medical Breakthrough

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

ROYAL BANK OF CANADA

Gilead Sciences

Regeneron Pharma

Biogen

Wells Fargo

Piper Sandler Cos

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

ORKA

ARKG

Oruka Therapeutics SVP Arjun Agarwal sold 10,290 shares at $59.07 each, totaling $607,830.30, representing a 38.55% decrease in his ownership. Post-sale, he holds 16,406 shares valued at $969,102.42. The transaction was made under a Rule 10b5-1 plan and disclosed to the SEC. The stock is currently trading down 5.8% at $58.34.

Market Beat

Oruka Therapeutics

Ark Genomic Revolution ETF

Barclays

UBS Group AG

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock

BMRN

BioMarin’s BMN 401 raised plasma PPi over 52 weeks in children but showed no meaningful rickets or growth improvement. Shares fell about 3% to ~$50.10 after the announcement.12HC Wainwright & Co. reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (BMRN) and lowered its price target for the stock from $55.00 to $50.00 per share.3

TradingView

BioMarin Pharma

iShares US Pharma

Health Care Select Sector SPDR

VG Health

Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50

ATRA

Rosen Law Firm is reminding investors who purchased Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, of the May 22, 2026, lead plaintiff deadline for a securities fraud lawsuit. Investors may be entitled to compensation without upfront fees. The lawsuit alleges that Atara made misleading statements regarding manufacturing issues and regulatory prospects, leading to investor damages when the truth emerged.

prnewswire

Atara Biotherap

iShares Global Healthcare

21:12 ETATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

LLYX

The company is riding an incredible tailwind.

Eli Lilly

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

Eli Lilly stock: Next stop $2,000?

REGN

LABD

Levi & Korsinsky is investigating Regeneron Pharmaceuticals (REGN) following significant stock losses after the failure of its Phase 3 melanoma trial of fianlimab + Libtayo. The stock dropped over 10% after the trial did not meet its primary endpoint. Shareholders who suffered losses are encouraged to contact the firm for potential legal recourse.

Direxion S&P Biotech Bear 3X

18:24 ETRegeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)

Health-care companies saw gains as traders shifted focus to underperforming sectors. However, Regeneron Pharmaceuticals experienced a significant drop in shares following a failed late-stage study of its fianlimab drug for melanoma. Additionally, an American contracted Ebola in the Democratic Republic of Congo amid an ongoing outbreak.

MorningStar

Health Care Up on Rotation Into Lagging Sectors — Health Care Roundup

NVAX

Novavax Inc. (NVAX) shares fell 1.43% to $8.93 on Monday, marking its second consecutive day of losses. The stock is currently 25.40% below its 52-week high of $11.97. In contrast, competitors like Johnson & Johnson and Merck saw gains, while Pfizer remained unchanged. Trading volume for Novavax was 4.8 million, surpassing its 50-day average of 4.4 million.

MarketWatch Automated

Novavax

Dow Jones Industrial Average

NASDAQ Composite Index

Johnson & Johnson

Pfizer

Merck

Factset Research

Novavax Inc. Stock Underperforms Monday When Compared To Competitors

Inovio Pharmaceuticals Inc. (INO) shares fell 6.15% to $1.22 on Monday, marking the second consecutive day of losses. The stock is now 59.05% below its 52-week high of $2.98. In contrast, competitors like Johnson & Johnson and Pfizer remained stable, while the overall market showed mixed results with the Dow up 0.32% and NASDAQ down 0.51%. Trading volume was 5.3 million, surpassing the 50-day average of 2.7 million.

Inovio Pharma

Inovio Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

CRBP

Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 9.79% to $9.95 on Monday, marking the third consecutive day of losses. The stock is currently 51.61% below its 52-week high of $20.56. In comparison, competitors had mixed results, with Vanda Pharmaceuticals down 3.18%, Fortress Biotech up 2.90%, and Viking Therapeutics down 5.22%. Trading volume was 232,939, below the 50-day average of 263,554.

Corbus Pharma

Vanda Pharma

Fortress Biotech

Viking Therap

Fortress Biotech Pref Share FBIOP 9.375 15/12/22

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors

IPHA

Innate Pharma to participate in the Jefferies Global Healthcare Conference | IPHA Stock News

StockTitan

Innate Pharma SA

Jefferies Financial